by: Parent Project Muscular Dystrophy
NS Pharma has announced that they will be presenting new, long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) at PPMD’s 2021 Virtual Annual Conference next month.
Check out PPMD’s Conference agenda and register today to join us virtually June 23-26.
Read the announcement:
VILTEPSO® (viltolarsen) injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference
PARAMUS, N.J., May 12, 2021 /PRNewswire/ — NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Shigenobu Maekawa), announced today that new, long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) injection will be presented at the PPMD 2021 Annual Conference being held virtually from June 23-26.
“This VILTEPSO data we are presenting at the PPMD Annual Conference represents some of the longest treatment times with exon-skipping therapy reported to date,” said Leslie Magnus, MD, Vice President, Medical Affairs. “This data, compared to a matched historical control group, provides information on the potential long-term effectiveness and safety of VILTEPSO that is critical for healthcare professionals and Duchenne patients and their caregivers.”
In addition to this Phase 2 open-label extension study, NS Pharma continues to investigate the efficacy and safety of VILTEPSO in the confirmatory Phase 3 RACER53 trial. This study was initiated in October 2019 and is currently enrolling patients. The purpose of this Phase 3 trial is to confirm the clinical findings that were submitted under the Accelerated Approval pathway.
About VILTEPSO® (viltolarsen) injection
Prior to its approval in the U.S., VILTEPSO was granted Priority Review as well as Rare Pediatric Disease, Orphan Drug and Fast Track Designations. In March 2020, VILTEPSO was approved in Japan for the treatment of patients with DMD who are amenable to exon 53 skipping therapy. Prior to its approval in Japan, VILTEPSO was granted with the SAKIGAKE designation, Orphan Drug designation, and designation of Conditional Early Approval System.
